Compare ANNX & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | MEG |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | 3500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.2M | 846.0M |
| IPO Year | 2020 | 2020 |
| Metric | ANNX | MEG |
|---|---|---|
| Price | $5.64 | $23.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $16.50 | ★ $33.50 |
| AVG Volume (30 Days) | ★ 2.3M | 328.0K |
| Earning Date | 03-02-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $826,323,000.00 |
| Revenue This Year | N/A | $19.70 |
| Revenue Next Year | N/A | $2.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.77 |
| 52 Week Low | $1.29 | $10.51 |
| 52 Week High | $7.18 | $32.00 |
| Indicator | ANNX | MEG |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 47.79 |
| Support Level | $6.10 | $21.92 |
| Resistance Level | $6.59 | $24.05 |
| Average True Range (ATR) | 0.43 | 0.99 |
| MACD | -0.14 | 0.15 |
| Stochastic Oscillator | 10.57 | 81.00 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.